TY - JOUR
T1 - Does a history of non-vertebral fracture identify women without osteoporosis for treatment?
AU - Ryder, Kathryn M.
AU - Cummings, Steven R.
AU - Palermo, Lisa
AU - Satterfield, Suzanne
AU - Bauer, Douglas C.
AU - Feldstein, Adrianne C.
AU - Schousboe, John T.
AU - Schwartz, Ann V.
AU - Ensrud, Kristine
N1 - Funding Information:
Acknowledgments: This research was sponsored by Merck Research Laboratories, Rahway, NJ. Members of the Fracture Intervention Trial Research Group are listed in reference 23.
PY - 2008/8
Y1 - 2008/8
N2 - BACKGROUND: Postmenopausal women with a prior fracture have an increased risk for future fracture. Whether a history of non-vertebral fracture defines a group of women with low bone mass but without osteoporosis for whom alendronate would prevent new non-vertebral fracture is not known. SUBJECTS AND METHODS: Secondary analysis of data from the Fracture Intervention Trial (FIT). Of 2,785 postmenopausal women with a T-score at the femoral neck between -1 and -2.5 and without prevalent radiographic vertebral deformity, 880 (31.6%) reported experiencing a fracture after 45 years of age. Women were randomized to placebo or alendronate (5 mg/day years for the first 2 years and 10 mg/day thereafter) and were followed for an average of 4.2±0.5 years. Incident non-vertebral fractures were confirmed by x-rays and radiology reports. RESULTS: In the placebo arm, a self-report of prior fracture identified women with a 1.5-fold (hazard ratio [RH] 1.46, 95% C.I. 1.04-2.04) increased risk for incident non-vertebral fracture. However, there was no evidence that the effect of alendronate differed across subgroups of women with (RH 1.26 for alendronate vs placebo, 95% C.I. 0.89-1.79) and without prior fracture (RH 1.02 for alendronate vs placebo, 95% C.I. 0.76-1.38; P=0.37 for interaction). CONCLUSION: Assessing a clinical risk factor, prior non-vertebral fracture, did not identify women with low bone mass for whom alendronate reduced future non-vertebral fracture risk.
AB - BACKGROUND: Postmenopausal women with a prior fracture have an increased risk for future fracture. Whether a history of non-vertebral fracture defines a group of women with low bone mass but without osteoporosis for whom alendronate would prevent new non-vertebral fracture is not known. SUBJECTS AND METHODS: Secondary analysis of data from the Fracture Intervention Trial (FIT). Of 2,785 postmenopausal women with a T-score at the femoral neck between -1 and -2.5 and without prevalent radiographic vertebral deformity, 880 (31.6%) reported experiencing a fracture after 45 years of age. Women were randomized to placebo or alendronate (5 mg/day years for the first 2 years and 10 mg/day thereafter) and were followed for an average of 4.2±0.5 years. Incident non-vertebral fractures were confirmed by x-rays and radiology reports. RESULTS: In the placebo arm, a self-report of prior fracture identified women with a 1.5-fold (hazard ratio [RH] 1.46, 95% C.I. 1.04-2.04) increased risk for incident non-vertebral fracture. However, there was no evidence that the effect of alendronate differed across subgroups of women with (RH 1.26 for alendronate vs placebo, 95% C.I. 0.89-1.79) and without prior fracture (RH 1.02 for alendronate vs placebo, 95% C.I. 0.76-1.38; P=0.37 for interaction). CONCLUSION: Assessing a clinical risk factor, prior non-vertebral fracture, did not identify women with low bone mass for whom alendronate reduced future non-vertebral fracture risk.
KW - Fracture
KW - Osteoporosis
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=49649126611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49649126611&partnerID=8YFLogxK
U2 - 10.1007/s11606-008-0622-0
DO - 10.1007/s11606-008-0622-0
M3 - Article
C2 - 18459010
AN - SCOPUS:49649126611
SN - 0884-8734
VL - 23
SP - 1177
EP - 1181
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 8
ER -